Best performing Mutual Funds for October 2026

Updated on July 15, 2026 , 38232 views

Based on criteria below we have selected Best Performing Mutual Funds for October, 2026. We have filtered funds having minimum 100 Crores of assets under management from all categories.

Ready to Invest?
Talk to our investment specialist

Criteria

AUM > 100 Crore's
Fund age > 1 Year
Funds from All Categories
Sorted on 1 month returns.
Categories of Funds
- Equity
- Debt
- Hybrid
- Gold
- global fund

How to Invest in Mutual Funds Online?

Open Free Investment Account for Lifetime at Fincash.com.

Complete your Registration and KYC Process

Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!

Get Started

Fund Selection Methodology used to find 11 funds

AUM Range: 100%20TO%20100000 Cr
Minimum fund age: 1 year
Sorted On : 1-month return (high to low)
No Of Funds: 11

Top 11 Best Mutual Funds October 2026

Fund	NAV	Net Assets (Cr)	Min Investment	Min SIP Investment	1 MO (%)	3 MO (%)	6 MO (%)	1 YR (%)	3 YR (%)	5 YR (%)	2024 (%)
SBI Healthcare Opportunities Fund Growth	₹506.495 ↑ 1.60	₹4,566	5,000	500	8.1	18.4	21.7	14.9	23.9	16.4	-3.5
UTI Healthcare Fund Growth	₹331.061 ↓ -4.05	₹1,217	5,000	500	6	16	19.3	11.6	25.2	14.2	-3.1
TATA India Pharma & Healthcare Fund Growth	₹33.0292 ↓ -0.30	₹1,387	5,000	150	5.2	12.3	11.1	6.7	20.7	13.1	-4.9
Motilal Oswal Midcap 30 Fund Growth	₹99.0958 ↑ 0.12	₹36,458	5,000	500	5	6.8	1.7	-4.2	18.7	21.9	-12.1
ICICI Prudential US Bluechip Equity Fund Growth	₹77.85 ↑ 1.23	₹3,699	5,000	100	4.9	6.6	3.4	21.9	13.3	11.5	15.8
Nippon India Pharma Fund Growth	₹560.958 ↓ -6.40	₹8,636	5,000	100	4.8	11.1	12	6.6	19.8	12.4	-3.3
Edelweiss ASEAN Equity Off-shore Fund Growth	₹37.856 ↑ 0.03	₹151	5,000	1,000	4.6	8.4	13.2	29.4	15.1	11	17.6
SBI Small Cap Fund Growth	₹181.089 ↑ 0.13	₹37,395	5,000	500	4.5	9.4	11.3	1.1	12.7	13.7	-4.9
Invesco India Growth Opportunities Fund Growth	₹109.61 ↓ -0.37	₹10,153	5,000	100	4.4	11	11.7	7.3	23.2	17.2	4.7
HDFC Long Term Advantage Fund Growth	₹595.168 ↑ 0.28	₹1,318	500	500	4.4	1.2	15.4	35.5	20.6	17.4
DSP Small Cap Fund Growth	₹221.566 ↓ -1.46	₹18,358	1,000	500	4.3	10.2	15.9	8	18	17.1	-2.8
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 16 Jul 26

Research Highlights & Commentary of 11 Funds showcased

Commentary	SBI Healthcare Opportunities Fund	UTI Healthcare Fund	TATA India Pharma & Healthcare Fund	Motilal Oswal Midcap 30 Fund	ICICI Prudential US Bluechip Equity Fund	Nippon India Pharma Fund	Edelweiss ASEAN Equity Off-shore Fund	SBI Small Cap Fund	Invesco India Growth Opportunities Fund	HDFC Long Term Advantage Fund	DSP Small Cap Fund
Point 1	Lower mid AUM (₹4,566 Cr).	Bottom quartile AUM (₹1,217 Cr).	Lower mid AUM (₹1,387 Cr).	Top quartile AUM (₹36,458 Cr).	Lower mid AUM (₹3,699 Cr).	Upper mid AUM (₹8,636 Cr).	Bottom quartile AUM (₹151 Cr).	Highest AUM (₹37,395 Cr).	Upper mid AUM (₹10,153 Cr).	Bottom quartile AUM (₹1,318 Cr).	Upper mid AUM (₹18,358 Cr).
Point 2	Established history (21+ yrs).	Oldest track record among peers (27 yrs).	Established history (10+ yrs).	Established history (12+ yrs).	Established history (14+ yrs).	Established history (22+ yrs).	Established history (15+ yrs).	Established history (16+ yrs).	Established history (18+ yrs).	Established history (25+ yrs).	Established history (19+ yrs).
Point 3	Rating: 2★ (lower mid).	Rating: 1★ (bottom quartile).	Not Rated.	Rating: 3★ (lower mid).	Rating: 4★ (upper mid).	Rating: 2★ (bottom quartile).	Rating: 3★ (lower mid).	Rating: 5★ (top quartile).	Top rated.	Rating: 3★ (upper mid).	Rating: 4★ (upper mid).
Point 4	Risk profile: High.	Risk profile: High.	Risk profile: High.	Risk profile: Moderately High.	Risk profile: High.	Risk profile: High.	Risk profile: High.	Risk profile: Moderately High.	Risk profile: Moderately High.	Risk profile: Moderately High.	Risk profile: Moderately High.
Point 5	5Y return: 16.42% (upper mid).	5Y return: 14.21% (lower mid).	5Y return: 13.09% (lower mid).	5Y return: 21.90% (top quartile).	5Y return: 11.48% (bottom quartile).	5Y return: 12.35% (bottom quartile).	5Y return: 10.98% (bottom quartile).	5Y return: 13.67% (lower mid).	5Y return: 17.20% (upper mid).	5Y return: 17.39% (top quartile).	5Y return: 17.11% (upper mid).
Point 6	3Y return: 23.94% (top quartile).	3Y return: 25.19% (top quartile).	3Y return: 20.73% (upper mid).	3Y return: 18.68% (lower mid).	3Y return: 13.29% (bottom quartile).	3Y return: 19.75% (lower mid).	3Y return: 15.07% (bottom quartile).	3Y return: 12.68% (bottom quartile).	3Y return: 23.23% (upper mid).	3Y return: 20.64% (upper mid).	3Y return: 18.02% (lower mid).
Point 7	1Y return: 14.90% (upper mid).	1Y return: 11.62% (upper mid).	1Y return: 6.68% (lower mid).	1Y return: -4.16% (bottom quartile).	1Y return: 21.95% (upper mid).	1Y return: 6.59% (bottom quartile).	1Y return: 29.42% (top quartile).	1Y return: 1.13% (bottom quartile).	1Y return: 7.25% (lower mid).	1Y return: 35.51% (top quartile).	1Y return: 7.97% (lower mid).
Point 8	Alpha: -0.04 (lower mid).	Alpha: 0.91 (upper mid).	Alpha: -7.02 (bottom quartile).	Alpha: -14.76 (bottom quartile).	Alpha: 2.81 (top quartile).	Alpha: -3.90 (bottom quartile).	Alpha: 0.00 (lower mid).	Alpha: 0.00 (lower mid).	Alpha: 2.71 (top quartile).	Alpha: 1.75 (upper mid).	Alpha: 0.00 (upper mid).
Point 9	Sharpe: 0.36 (upper mid).	Sharpe: 0.42 (upper mid).	Sharpe: 0.14 (lower mid).	Sharpe: -0.55 (bottom quartile).	Sharpe: 1.83 (top quartile).	Sharpe: 0.07 (lower mid).	Sharpe: 1.74 (upper mid).	Sharpe: -0.22 (bottom quartile).	Sharpe: 0.07 (bottom quartile).	Sharpe: 2.27 (top quartile).	Sharpe: 0.13 (lower mid).
Point 10	Information ratio: -0.40 (lower mid).	Information ratio: 0.08 (top quartile).	Information ratio: -0.62 (bottom quartile).	Information ratio: -0.36 (lower mid).	Information ratio: -1.70 (bottom quartile).	Information ratio: -0.93 (bottom quartile).	Information ratio: 0.00 (upper mid).	Information ratio: 0.00 (upper mid).	Information ratio: 0.87 (top quartile).	Information ratio: -0.15 (lower mid).	Information ratio: 0.00 (upper mid).

SBI Healthcare Opportunities Fund

Lower mid AUM (₹4,566 Cr).
Established history (21+ yrs).
Rating: 2★ (lower mid).
Risk profile: High.
5Y return: 16.42% (upper mid).
3Y return: 23.94% (top quartile).
1Y return: 14.90% (upper mid).
Alpha: -0.04 (lower mid).
Sharpe: 0.36 (upper mid).
Information ratio: -0.40 (lower mid).

UTI Healthcare Fund

Bottom quartile AUM (₹1,217 Cr).
Oldest track record among peers (27 yrs).
Rating: 1★ (bottom quartile).
Risk profile: High.
5Y return: 14.21% (lower mid).
3Y return: 25.19% (top quartile).
1Y return: 11.62% (upper mid).
Alpha: 0.91 (upper mid).
Sharpe: 0.42 (upper mid).
Information ratio: 0.08 (top quartile).

TATA India Pharma & Healthcare Fund

Lower mid AUM (₹1,387 Cr).
Established history (10+ yrs).
Not Rated.
Risk profile: High.
5Y return: 13.09% (lower mid).
3Y return: 20.73% (upper mid).
1Y return: 6.68% (lower mid).
Alpha: -7.02 (bottom quartile).
Sharpe: 0.14 (lower mid).
Information ratio: -0.62 (bottom quartile).

Motilal Oswal Midcap 30 Fund

Top quartile AUM (₹36,458 Cr).
Established history (12+ yrs).
Rating: 3★ (lower mid).
Risk profile: Moderately High.
5Y return: 21.90% (top quartile).
3Y return: 18.68% (lower mid).
1Y return: -4.16% (bottom quartile).
Alpha: -14.76 (bottom quartile).
Sharpe: -0.55 (bottom quartile).
Information ratio: -0.36 (lower mid).

ICICI Prudential US Bluechip Equity Fund

Lower mid AUM (₹3,699 Cr).
Established history (14+ yrs).
Rating: 4★ (upper mid).
Risk profile: High.
5Y return: 11.48% (bottom quartile).
3Y return: 13.29% (bottom quartile).
1Y return: 21.95% (upper mid).
Alpha: 2.81 (top quartile).
Sharpe: 1.83 (top quartile).
Information ratio: -1.70 (bottom quartile).

Nippon India Pharma Fund

Upper mid AUM (₹8,636 Cr).
Established history (22+ yrs).
Rating: 2★ (bottom quartile).
Risk profile: High.
5Y return: 12.35% (bottom quartile).
3Y return: 19.75% (lower mid).
1Y return: 6.59% (bottom quartile).
Alpha: -3.90 (bottom quartile).
Sharpe: 0.07 (lower mid).
Information ratio: -0.93 (bottom quartile).

Edelweiss ASEAN Equity Off-shore Fund

Bottom quartile AUM (₹151 Cr).
Established history (15+ yrs).
Rating: 3★ (lower mid).
Risk profile: High.
5Y return: 10.98% (bottom quartile).
3Y return: 15.07% (bottom quartile).
1Y return: 29.42% (top quartile).
Alpha: 0.00 (lower mid).
Sharpe: 1.74 (upper mid).
Information ratio: 0.00 (upper mid).

SBI Small Cap Fund

Highest AUM (₹37,395 Cr).
Established history (16+ yrs).
Rating: 5★ (top quartile).
Risk profile: Moderately High.
5Y return: 13.67% (lower mid).
3Y return: 12.68% (bottom quartile).
1Y return: 1.13% (bottom quartile).
Alpha: 0.00 (lower mid).
Sharpe: -0.22 (bottom quartile).
Information ratio: 0.00 (upper mid).

Invesco India Growth Opportunities Fund

Upper mid AUM (₹10,153 Cr).
Established history (18+ yrs).
Top rated.
Risk profile: Moderately High.
5Y return: 17.20% (upper mid).
3Y return: 23.23% (upper mid).
1Y return: 7.25% (lower mid).
Alpha: 2.71 (top quartile).
Sharpe: 0.07 (bottom quartile).
Information ratio: 0.87 (top quartile).

HDFC Long Term Advantage Fund

Bottom quartile AUM (₹1,318 Cr).
Established history (25+ yrs).
Rating: 3★ (upper mid).
Risk profile: Moderately High.
5Y return: 17.39% (top quartile).
3Y return: 20.64% (upper mid).
1Y return: 35.51% (top quartile).
Alpha: 1.75 (upper mid).
Sharpe: 2.27 (top quartile).
Information ratio: -0.15 (lower mid).

DSP Small Cap Fund

Upper mid AUM (₹18,358 Cr).
Established history (19+ yrs).
Rating: 4★ (upper mid).
Risk profile: Moderately High.
5Y return: 17.11% (upper mid).
3Y return: 18.02% (lower mid).
1Y return: 7.97% (lower mid).
Alpha: 0.00 (upper mid).
Sharpe: 0.13 (lower mid).
Information ratio: 0.00 (upper mid).

About the Fincash Research Team

At Fincash, our mission is to help investors make informed, confident decisions. With over 10 years in Mutual Fund distribution, our team blends deep industry expertise with a commitment to transparency, accuracy, and investor education.

Who We Are

AMFI Registration No.: 112358
MCA CIN: U74999MH2016PTC282153
Location: Thane, Maharashtra, India
Experience: 10+ years in Mutual Fund distribution

Our Expertise

Certified Mutual Fund Distributors with hands-on advisory experience.
Market analysts tracking performance, macro trends, and sectors.
Data specialists processing NAVs, allocations, and risk metrics from Morning Star.

Our Research Process

Data sourcing: SEBI-registered fund houses & verified third-party provider Morning Star
Screening: Returns, manager track record, expenses, sector mix, risk-adjusted metrics.
Expert review: Senior team members review every article and list for accuracy.
Updates: Regular refreshes so performance data reflects current market conditions.

Why Trust Us

Regulated & compliant: AMFI-registered and MCA-incorporated.
Investor-first: No pay-to-promote lists; suitability and performance drive coverage.
Education-focused: We simplify complex concepts for everyday investors.

Disclaimer

Content is for educational and informational purposes only and is not investment advice. Please consider your risk profile and consult a financial advisor before investing.

*Below is the list of top Mutual Funds for October, 2026 having Assets >= 100 Crore

1. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

Research Highlights for SBI Healthcare Opportunities Fund

Lower mid AUM (₹4,566 Cr).
Established history (21+ yrs).
Rating: 2★ (lower mid).
Risk profile: High.
5Y return: 16.42% (upper mid).
3Y return: 23.94% (top quartile).
1Y return: 14.90% (upper mid).
Alpha: -0.04 (lower mid).
Sharpe: 0.36 (upper mid).
Information ratio: -0.40 (lower mid).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~97%).
High-quality debt (AAA/AA ~100%).
Largest holding Sun Pharmaceuticals Industries Ltd (~11.0%).

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund Growth
Launch Date	31 Dec 04
NAV (16 Jul 26)	₹506.495 ↑ 1.60 (0.32 %)
Net Assets (Cr)	₹4,566 on 31 May 26
Category	Equity - Sectoral
AMC	SBI Funds Management Private Limited
Rating	☆☆
Risk	High
Expense Ratio	1.97
Sharpe Ratio	0.36
Information Ratio	-0.4
Alpha Ratio	-0.04
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,662
30 Jun 23	₹11,165
30 Jun 24	₹15,491
30 Jun 25	₹18,739
30 Jun 26	₹21,357

SBI Healthcare Opportunities Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689 Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	8.1%
3 Month	18.4%
6 Month	21.7%
1 Year	14.9%
3 Year	23.9%
5 Year	16.4%
10 Year
15 Year
Since launch	15.7%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-3.5%
2023	42.2%
2022	38.2%
2021	-6%
2020	20.1%
2019	65.8%
2018	-0.5%
2017	-9.9%
2016	2.1%
2015	-14%

Fund Manager information for SBI Healthcare Opportunities Fund

Name	Since	Tenure
Tanmaya Desai	1 Jun 11	15.09 Yr.

Data below for SBI Healthcare Opportunities Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Health Care	88.67%
Basic Materials	8.82%

Asset Allocation

Asset Class	Value
Cash	2.45%
Equity	97.49%
Debt	0.06%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Dec 17 \| SUNPHARMA	11%	₹504 Cr	2,800,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	7%	₹300 Cr	450,000
Acutaas Chemicals Ltd (Basic Materials) Equity, Since 30 Jun 24 \| 543349	6%	₹282 Cr	900,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Jan 26 \| APOLLOHOSP	5%	₹245 Cr	300,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 21 \| MAXHEALTH	5%	₹217 Cr	2,250,000
Aurobindo Pharma Ltd (Healthcare) Equity, Since 31 Mar 26 \| AUROPHARMA	4%	₹178 Cr	1,250,000 ↑ 250,000
Aster DM Healthcare Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 24 \| ASTERDM	4%	₹175 Cr	2,400,000
Laurus Labs Ltd (Healthcare) Equity, Since 31 Aug 23 \| LAURUSLABS	4%	₹163 Cr	1,200,000
Biocon Ltd (Healthcare) Equity, Since 30 Nov 24 \| BIOCON	4%	₹161 Cr	3,750,000
Torrent Pharmaceuticals Ltd (Healthcare) Equity, Since 30 Jun 21 \| TORNTPHARM	3%	₹159 Cr	360,000

2. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

Research Highlights for UTI Healthcare Fund

Bottom quartile AUM (₹1,217 Cr).
Oldest track record among peers (27 yrs).
Rating: 1★ (bottom quartile).
Risk profile: High.
5Y return: 14.21% (lower mid).
3Y return: 25.19% (top quartile).
1Y return: 11.62% (upper mid).
Alpha: 0.91 (upper mid).
Sharpe: 0.42 (upper mid).
Information ratio: 0.08 (top quartile).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~94%).
Largest holding Sun Pharmaceuticals Industries Ltd (~8.9%).

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund Growth
Launch Date	28 Jun 99
NAV (17 Jul 26)	₹331.061 ↓ -4.05 (-1.21 %)
Net Assets (Cr)	₹1,217 on 31 May 26
Category	Equity - Sectoral
AMC	UTI Asset Management Company Ltd
Rating	☆
Risk	High
Expense Ratio	2.26
Sharpe Ratio	0.42
Information Ratio	0.08
Alpha Ratio	0.91
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,478
30 Jun 23	₹10,006
30 Jun 24	₹14,264
30 Jun 25	₹17,337
30 Jun 26	₹19,764

UTI Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹436,710.
Net Profit of ₹136,710 Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	6%
3 Month	16%
6 Month	19.3%
1 Year	11.6%
3 Year	25.2%
5 Year	14.2%
10 Year
15 Year
Since launch	15%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-3.1%
2023	42.9%
2022	38.2%
2021	-12.3%
2020	19.1%
2019	67.4%
2018	1.2%
2017	-7.5%
2016	6.2%
2015	-9.7%

Fund Manager information for UTI Healthcare Fund

Name	Since	Tenure
Kamal Gada	2 May 22	4.17 Yr.

Data below for UTI Healthcare Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Health Care	94.45%

Asset Allocation

Asset Class	Value
Cash	5.55%
Equity	94.45%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 06 \| SUNPHARMA	9%	₹108 Cr	600,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	5%	₹59 Cr	88,814 ↑ 28,076
Ajanta Pharma Ltd (Healthcare) Equity, Since 31 Jul 17 \| AJANTPHARM	5%	₹57 Cr	195,295 ↓ -41,216
Gland Pharma Ltd (Healthcare) Equity, Since 30 Nov 20 \| GLAND	4%	₹48 Cr	215,251
Lupin Ltd (Healthcare) Equity, Since 28 Feb 25 \| LUPIN	4%	₹46 Cr	203,834 ↓ -6,166
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Apr 21 \| APOLLOHOSP	4%	₹43 Cr	53,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 28 Feb 18 \| DRREDDY	3%	₹38 Cr	290,000
Caplin Point Laboratories Ltd (Healthcare) Equity, Since 31 Dec 23 \| CAPLIPOINT	3%	₹37 Cr	185,000 ↑ 39,847
Alkem Laboratories Ltd (Healthcare) Equity, Since 31 May 21 \| ALKEM	3%	₹37 Cr	68,000
Fortis Healthcare Ltd (Healthcare) Equity, Since 31 Dec 20 \| FORTIS	3%	₹37 Cr	400,000

3. TATA India Pharma & Healthcare Fund

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

Research Highlights for TATA India Pharma & Healthcare Fund

Lower mid AUM (₹1,387 Cr).
Established history (10+ yrs).
Not Rated.
Risk profile: High.
5Y return: 13.09% (lower mid).
3Y return: 20.73% (upper mid).
1Y return: 6.68% (lower mid).
Alpha: -7.02 (bottom quartile).
Sharpe: 0.14 (lower mid).
Information ratio: -0.62 (bottom quartile).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~99%).
Largest holding Sun Pharmaceuticals Industries Ltd (~9.4%).

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund Growth
Launch Date	28 Dec 15
NAV (17 Jul 26)	₹33.0292 ↓ -0.30 (-0.91 %)
Net Assets (Cr)	₹1,387 on 31 May 26
Category	Equity - Sectoral
AMC	Tata Asset Management Limited
Rating	Not Rated
Risk	High
Expense Ratio	2.17
Sharpe Ratio	0.14
Information Ratio	-0.62
Alpha Ratio	-7.02
Min Investment	5,000
Min SIP Investment	150
Exit Load	0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,951
30 Jun 23	₹10,628
30 Jun 24	₹15,238
30 Jun 25	₹17,550
30 Jun 26	₹18,791

TATA India Pharma & Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹426,080.
Net Profit of ₹126,080 Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	5.2%
3 Month	12.3%
6 Month	11.1%
1 Year	6.7%
3 Year	20.7%
5 Year	13.1%
10 Year
15 Year
Since launch	12%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-4.9%
2023	40.4%
2022	36.6%
2021	-8%
2020	19.1%
2019	64.4%
2018	5.5%
2017	-2.6%
2016	4.7%
2015	-14.7%

Fund Manager information for TATA India Pharma & Healthcare Fund

Name	Since	Tenure
Rajat Srivastava	16 Sep 24	1.79 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Health Care	93.6%
Basic Materials	3.96%
Consumer Defensive	1.35%
Financial Services	0.4%

Asset Allocation

Asset Class	Value
Cash	0.7%
Equity	99.3%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Jan 16 \| SUNPHARMA	9%	₹130 Cr	723,130
HealthCare Global Enterprises Ltd (Healthcare) Equity, Since 31 Dec 18 \| HCG	6%	₹81 Cr	1,276,727 ↑ 15,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	6%	₹80 Cr	120,600
Abbott India Ltd (Healthcare) Equity, Since 30 Sep 25 \| ABBOTINDIA	5%	₹75 Cr	27,953
Cipla Ltd (Healthcare) Equity, Since 30 Apr 20 \| CIPLA	5%	₹72 Cr	512,754
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Jul 25 \| MAXHEALTH	5%	₹67 Cr	690,488
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Dec 16 \| APOLLOHOSP	5%	₹63 Cr	77,345 ↑ 6,861
Rainbow Childrens Medicare Ltd (Healthcare) Equity, Since 31 Jul 25 \| 543524	5%	₹63 Cr	454,338 ↑ 7,205
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 31 Aug 18 \| DRREDDY	4%	₹56 Cr	428,116 ↑ 54,652
Mankind Pharma Ltd (Healthcare) Equity, Since 30 Apr 23 \| MANKIND	4%	₹52 Cr	220,018

4. Motilal Oswal Midcap 30 Fund

(Erstwhile Motilal Oswal MOSt Focused Midcap 30 Fund)

The investment objective of the Scheme is to achieve long term capital appreciation by investing in a maximum of 30 quality mid-cap companies having long-term competitive advantages and potential for growth. However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Research Highlights for Motilal Oswal Midcap 30 Fund

Top quartile AUM (₹36,458 Cr).
Established history (12+ yrs).
Rating: 3★ (lower mid).
Risk profile: Moderately High.
5Y return: 21.90% (top quartile).
3Y return: 18.68% (lower mid).
1Y return: -4.16% (bottom quartile).
Alpha: -14.76 (bottom quartile).
Sharpe: -0.55 (bottom quartile).
Information ratio: -0.36 (lower mid).
Higher exposure to Financial Services vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~93%).
Largest holding One97 Communications Ltd (~7.3%).

Below is the key information for Motilal Oswal Midcap 30 Fund

Motilal Oswal Midcap 30 Fund Growth
Launch Date	24 Feb 14
NAV (17 Jul 26)	₹99.0958 ↑ 0.12 (0.12 %)
Net Assets (Cr)	₹36,458 on 31 May 26
Category	Equity - Mid Cap
AMC	Motilal Oswal Asset Management Co. Ltd
Rating	☆☆☆
Risk	Moderately High
Expense Ratio	1.56
Sharpe Ratio	-0.55
Information Ratio	-0.36
Alpha Ratio	-14.76
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹11,908
30 Jun 23	₹16,418
30 Jun 24	₹26,938
30 Jun 25	₹29,503
30 Jun 26	₹26,510

Motilal Oswal Midcap 30 Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹518,033.
Net Profit of ₹218,033 Invest Now

Returns for Motilal Oswal Midcap 30 Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	5%
3 Month	6.8%
6 Month	1.7%
1 Year	-4.2%
3 Year	18.7%
5 Year	21.9%
10 Year
15 Year
Since launch	20.3%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-12.1%
2023	57.1%
2022	41.7%
2021	10.7%
2020	55.8%
2019	9.3%
2018	9.7%
2017	-12.7%
2016	30.8%
2015	5.2%

Fund Manager information for Motilal Oswal Midcap 30 Fund

Name	Since	Tenure
Varun Sharma	21 Jan 26	0.44 Yr.
Swapnil Mayekar	18 Nov 25	0.62 Yr.
Ajay Khandelwal	1 Oct 24	1.75 Yr.
Ankit Agarwal	21 Jan 26	0.44 Yr.
Rakesh Shetty	22 Nov 22	3.61 Yr.

Data below for Motilal Oswal Midcap 30 Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Financial Services	31.02%
Technology	26.84%
Industrials	13.76%
Consumer Cyclical	13.41%
Communication Services	3.08%
Real Estate	2.81%
Health Care	2.46%

Asset Allocation

Asset Class	Value
Cash	6.63%
Equity	93.37%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
One97 Communications Ltd (Technology) Equity, Since 30 Sep 24 \| PAYTM	7%	₹2,659 Cr	23,765,865
Coforge Ltd (Technology) Equity, Since 31 Mar 23 \| COFORGE	6%	₹2,233 Cr	15,703,312 ↓ -979,603
Kalyan Jewellers India Ltd (Consumer Cyclical) Equity, Since 29 Feb 24 \| KALYANKJIL	6%	₹2,180 Cr	61,413,395
KEI Industries Ltd (Industrials) Equity, Since 30 Nov 24 \| KEI	6%	₹2,123 Cr	4,030,834
Eternal Ltd (Consumer Cyclical) Equity, Since 31 Aug 25 \| ETERNAL	6%	₹2,115 Cr	84,386,866
Persistent Systems Ltd (Technology) Equity, Since 31 Jan 23 \| PERSISTENT	6%	₹2,091 Cr	4,026,493
Aditya Birla Capital Ltd (Financial Services) Equity, Since 30 Jun 25 \| ABCAPITAL	5%	₹1,906 Cr	52,459,381 ↓ -1,000,000
Billionbrains Garage Ventures Ltd (Financial Services) Equity, Since 31 Jan 26 \| GROWW	4%	₹1,564 Cr	84,616,660
Multi Commodity Exchange of India Ltd (Financial Services) Equity, Since 31 Jan 26 \| MCX	4%	₹1,539 Cr	5,209,458
BSE Ltd (Financial Services) Equity, Since 30 Nov 25 \| BSE	4%	₹1,451 Cr	3,500,830 ↓ -256,232

5. ICICI Prudential US Bluechip Equity Fund

The investment objective of ICICI Prudential US Bluechip Equity Fund is to provide long term capital appreciation to investors by primarily investing in equity and equity related securities (including ADRs/GDRs issued by Indian and foreign companies) of companies listed on New York Stock Exchange and/or NASDAQ. However, there can be no assurance that the investment objective of the Scheme will be realized.

Research Highlights for ICICI Prudential US Bluechip Equity Fund

Lower mid AUM (₹3,699 Cr).
Established history (14+ yrs).
Rating: 4★ (upper mid).
Risk profile: High.
5Y return: 11.48% (bottom quartile).
3Y return: 13.29% (bottom quartile).
1Y return: 21.95% (upper mid).
Alpha: 2.81 (top quartile).
Sharpe: 1.83 (top quartile).
Information ratio: -1.70 (bottom quartile).
Higher exposure to Technology vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~97%).
Largest holding Microsoft Corp (~2.7%).

Below is the key information for ICICI Prudential US Bluechip Equity Fund

ICICI Prudential US Bluechip Equity Fund Growth
Launch Date	6 Jul 12
NAV (16 Jul 26)	₹77.85 ↑ 1.23 (1.61 %)
Net Assets (Cr)	₹3,699 on 31 May 26
Category	Equity - Global
AMC	ICICI Prudential Asset Management Company Limited
Rating	☆☆☆☆
Risk	High
Expense Ratio	2.06
Sharpe Ratio	1.83
Information Ratio	-1.7
Alpha Ratio	2.81
Min Investment	5,000
Min SIP Investment	100
Exit Load	0-3 Months (3%),3-12 Months (1%),12 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,919
30 Jun 23	₹11,609
30 Jun 24	₹12,737
30 Jun 25	₹13,895
30 Jun 26	₹16,289

ICICI Prudential US Bluechip Equity Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹405,518.
Net Profit of ₹105,518 Invest Now

Returns for ICICI Prudential US Bluechip Equity Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	4.9%
3 Month	6.6%
6 Month	3.4%
1 Year	21.9%
3 Year	13.3%
5 Year	11.5%
10 Year
15 Year
Since launch	15.8%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	15.8%
2023	10.4%
2022	30.6%
2021	-7.1%
2020	22.5%
2019	18.6%
2018	34.3%
2017	5.2%
2016	14.1%
2015	11.6%

Fund Manager information for ICICI Prudential US Bluechip Equity Fund

Name	Since	Tenure
Ritesh Lunawat	13 Sep 24	1.8 Yr.
Sharmila D'Silva	1 Jul 22	4 Yr.
Nitya Mishra	4 Nov 24	1.65 Yr.

Data below for ICICI Prudential US Bluechip Equity Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Technology	28.28%
Consumer Defensive	16.84%
Health Care	16.55%
Industrials	14.5%
Financial Services	8.99%
Consumer Cyclical	6.89%
Communication Services	2.83%
Basic Materials	1.4%
Real Estate	0.97%

Asset Allocation

Asset Class	Value
Cash	2.76%
Equity	97.24%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Microsoft Corp (Technology) Equity, Since 30 Jun 16 \| MSFT	3%	₹98 Cr	22,897
Agilent Technologies Inc (Healthcare) Equity, Since 30 Jun 23 \| AG8	3%	₹98 Cr	75,728
Clorox Co (Consumer Defensive) Equity, Since 30 Jun 25 \| CXX	3%	₹94 Cr	110,000 ↑ 10,000
Kenvue Inc (Consumer Defensive) Equity, Since 31 Mar 24 \| J4D	3%	₹94 Cr	568,560
Fortinet Inc (Technology) Equity, Since 30 Sep 25 \| FTNT	2%	₹92 Cr	69,600 ↓ -31,900
NXP Semiconductors NV (Technology) Equity, Since 30 Sep 24 \| 0EDE	2%	₹91 Cr	29,750 ↓ -14,650
The Estee Lauder Companies Inc Class A (Consumer Defensive) Equity, Since 30 Jun 23 \| EL	2%	₹90 Cr	106,367
Danaher Corp (Healthcare) Equity, Since 31 Dec 24 \| DHRC	2%	₹88 Cr	50,500 ↑ 2,200
Salesforce Inc (Technology) Equity, Since 31 Dec 18 \| CRM	2%	₹86 Cr	47,195 ↓ -5,300
Mondelez International Inc Class A (Consumer Defensive) Equity, Since 31 Dec 24 \| MDLZ	2%	₹84 Cr	144,400

6. Nippon India Pharma Fund

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Research Highlights for Nippon India Pharma Fund

Upper mid AUM (₹8,636 Cr).
Established history (22+ yrs).
Rating: 2★ (bottom quartile).
Risk profile: High.
5Y return: 12.35% (bottom quartile).
3Y return: 19.75% (lower mid).
1Y return: 6.59% (bottom quartile).
Alpha: -3.90 (bottom quartile).
Sharpe: 0.07 (lower mid).
Information ratio: -0.93 (bottom quartile).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~98%).
Largest holding Sun Pharmaceuticals Industries Ltd (~13.3%).

Below is the key information for Nippon India Pharma Fund

Nippon India Pharma Fund Growth
Launch Date	5 Jun 04
NAV (17 Jul 26)	₹560.958 ↓ -6.40 (-1.13 %)
Net Assets (Cr)	₹8,636 on 31 May 26
Category	Equity - Sectoral
AMC	Nippon Life Asset Management Ltd.
Rating	☆☆
Risk	High
Expense Ratio	1.81
Sharpe Ratio	0.07
Information Ratio	-0.93
Alpha Ratio	-3.9
Min Investment	5,000
Min SIP Investment	100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,540
30 Jun 23	₹10,376
30 Jun 24	₹14,608
30 Jun 25	₹16,993
30 Jun 26	₹18,254

Nippon India Pharma Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹415,684.
Net Profit of ₹115,684 Invest Now

Returns for Nippon India Pharma Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	4.8%
3 Month	11.1%
6 Month	12%
1 Year	6.6%
3 Year	19.8%
5 Year	12.4%
10 Year
15 Year
Since launch	20%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-3.3%
2023	34%
2022	39.2%
2021	-9.9%
2020	23.9%
2019	66.4%
2018	1.7%
2017	3.6%
2016	7.6%
2015	-10.6%

Fund Manager information for Nippon India Pharma Fund

Name	Since	Tenure
Sailesh Raj Bhan	1 Apr 05	21.26 Yr.
Kinjal Desai	25 May 18	8.11 Yr.
Amber Singhania	11 Mar 26	0.31 Yr.

Data below for Nippon India Pharma Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Health Care	97.92%

Asset Allocation

Asset Class	Value
Cash	2.08%
Equity	97.92%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 09 \| SUNPHARMA	13%	₹1,153 Cr	6,406,349
Lupin Ltd (Healthcare) Equity, Since 31 Aug 08 \| LUPIN	7%	₹631 Cr	2,783,991 ↓ -100,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 30 Jun 11 \| DRREDDY	7%	₹580 Cr	4,449,746
Cipla Ltd (Healthcare) Equity, Since 31 May 08 \| CIPLA	6%	₹532 Cr	3,795,054 ↑ 300,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	6%	₹501 Cr	750,754 ↓ -100,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Sep 20 \| APOLLOHOSP	5%	₹449 Cr	548,795
Mankind Pharma Ltd (Healthcare) Equity, Since 30 Apr 23 \| MANKIND	4%	₹340 Cr	1,431,195 ↑ 300,000
Medplus Health Services Ltd (Healthcare) Equity, Since 30 Nov 22 \| MEDPLUS	4%	₹317 Cr	3,545,229 ↓ -82,048
Sai Life Sciences Ltd (Healthcare) Equity, Since 31 Dec 24 \| SAILIFE	3%	₹296 Cr	2,555,745
Ajanta Pharma Ltd (Healthcare) Equity, Since 30 Apr 22 \| AJANTPHARM	3%	₹277 Cr	946,323

7. Edelweiss ASEAN Equity Off-shore Fund

The primary investment objective of the Scheme is to provide long term capital growth by investing predominantly in JPMorgan Funds – JF ASEAN Equity Fund, an equity fund which invests primarily in companies of countries which are members of the Association of South East Asian Nations (ASEAN). However, there can be no assurance that the investment objective of the Scheme will be realized.

Research Highlights for Edelweiss ASEAN Equity Off-shore Fund

Bottom quartile AUM (₹151 Cr).
Established history (15+ yrs).
Rating: 3★ (lower mid).
Risk profile: High.
5Y return: 10.98% (bottom quartile).
3Y return: 15.07% (bottom quartile).
1Y return: 29.42% (top quartile).
Alpha: 0.00 (lower mid).
Sharpe: 1.74 (upper mid).
Information ratio: 0.00 (upper mid).
Higher exposure to Financial Services vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~96%).
Largest holding JPM ASEAN Equity I acc USD (~98.0%).
Top-3 holdings concentration ~100.3%.

Below is the key information for Edelweiss ASEAN Equity Off-shore Fund

Edelweiss ASEAN Equity Off-shore Fund Growth
Launch Date	1 Jul 11
NAV (16 Jul 26)	₹37.856 ↑ 0.03 (0.08 %)
Net Assets (Cr)	₹151 on 31 May 26
Category	Equity - Global
AMC	Edelweiss Asset Management Limited
Rating	☆☆☆
Risk	High
Expense Ratio	1.42
Sharpe Ratio	1.74
Information Ratio	0
Alpha Ratio	0
Min Investment	5,000
Min SIP Investment	1,000
Exit Load	0-12 Months (1%),12 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹9,586
30 Jun 23	₹10,517
30 Jun 24	₹10,777
30 Jun 25	₹12,684
30 Jun 26	₹15,564

Edelweiss ASEAN Equity Off-shore Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹395,578.
Net Profit of ₹95,578 Invest Now

Returns for Edelweiss ASEAN Equity Off-shore Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	4.6%
3 Month	8.4%
6 Month	13.2%
1 Year	29.4%
3 Year	15.1%
5 Year	11%
10 Year
15 Year
Since launch	9.3%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	17.6%
2023	14.5%
2022	-1.4%
2021	4.8%
2020	6.3%
2019	2.3%
2018	12%
2017	-2.1%
2016	21.9%
2015	9.6%

Fund Manager information for Edelweiss ASEAN Equity Off-shore Fund

Name	Since	Tenure
Bhavesh Jain	27 Sep 19	6.76 Yr.
Bharat Lahoti	1 Oct 21	4.75 Yr.

Data below for Edelweiss ASEAN Equity Off-shore Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Financial Services	39.62%
Industrials	23.47%
Communication Services	7.09%
Consumer Cyclical	6.1%
Technology	4.79%
Basic Materials	4.7%
Utility	2.99%
Real Estate	2.95%
Health Care	2.48%
Consumer Defensive	1.38%
Energy	0.82%

Asset Allocation

Asset Class	Value
Cash	3.6%
Equity	96.4%
Other	0%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
JPM ASEAN Equity I acc USD Investment Fund \| -	98%	₹148 Cr	68,777
Clearing Corporation Of India Ltd. CBLO/Reverse Repo \| -	2%	₹3 Cr
Net Receivables/(Payables) CBLO \| -	0%	₹0 Cr
Accrued Interest CBLO \| -	0%	₹0 Cr

8. SBI Small Cap Fund

(Erstwhile SBI Small & Midcap Fund)

The Scheme seeks to generate income and long term capital appreciation by investing in a diversified portfolio of predominantly in equity and equity related securities of small & midcap Companies

Research Highlights for SBI Small Cap Fund

Highest AUM (₹37,395 Cr).
Established history (16+ yrs).
Rating: 5★ (top quartile).
Risk profile: Moderately High.
5Y return: 13.67% (lower mid).
3Y return: 12.68% (bottom quartile).
1Y return: 1.13% (bottom quartile).
Alpha: 0.00 (lower mid).
Sharpe: -0.22 (bottom quartile).
Information ratio: 0.00 (upper mid).
Higher exposure to Consumer Cyclical vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~92%).
High-quality debt (AAA/AA ~100%).
Largest holding Ather Energy Ltd (~5.2%).

Below is the key information for SBI Small Cap Fund

SBI Small Cap Fund Growth
Launch Date	9 Sep 09
NAV (17 Jul 26)	₹181.089 ↑ 0.13 (0.07 %)
Net Assets (Cr)	₹37,395 on 31 May 26
Category	Equity - Small Cap
AMC	SBI Funds Management Private Limited
Rating	☆☆☆☆☆
Risk	Moderately High
Expense Ratio	1.58
Sharpe Ratio	-0.22
Information Ratio	0
Alpha Ratio	0
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹10,523
30 Jun 23	₹13,391
30 Jun 24	₹19,005
30 Jun 25	₹19,070
30 Jun 26	₹19,531

SBI Small Cap Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹426,080.
Net Profit of ₹126,080 Invest Now

Returns for SBI Small Cap Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	4.5%
3 Month	9.4%
6 Month	11.3%
1 Year	1.1%
3 Year	12.7%
5 Year	13.7%
10 Year
15 Year
Since launch	18.8%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-4.9%
2023	24.1%
2022	25.3%
2021	8.1%
2020	47.6%
2019	33.6%
2018	6.1%
2017	-19.6%
2016	78.7%
2015	1.3%

Fund Manager information for SBI Small Cap Fund

Name	Since	Tenure
R. Srinivasan	16 Nov 13	12.63 Yr.

Data below for SBI Small Cap Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Consumer Cyclical	25.82%
Industrials	22.25%
Financial Services	14.47%
Basic Materials	13.64%
Technology	5.46%
Consumer Defensive	3.43%
Health Care	2.5%
Real Estate	0.77%
Communication Services	0.37%

Asset Allocation

Asset Class	Value
Cash	7.93%
Equity	91.9%
Debt	0.17%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Ather Energy Ltd (Consumer Cyclical) Equity, Since 30 Apr 25 \| ATHERENERG	5%	₹1,938 Cr	20,096,960
Nifty Index 30-06-2026 Derivatives, Since 31 May 26 \| -	3%	₹1,188 Cr	500,175 ↑ 500,175
Navin Fluorine International Ltd (Basic Materials) Equity, Since 31 Mar 20 \| NAVINFLUOR	3%	₹1,163 Cr	1,631,795 ↑ 58,216
Honeywell Automation India Ltd (Industrials) Equity, Since 31 Dec 25 \| HONAUT	3%	₹1,059 Cr	298,145
Kalpataru Projects International Ltd (Industrials) Equity, Since 31 May 20 \| KPIL	3%	₹1,031 Cr	7,900,000
ZF Commercial Vehicle Control Systems India Ltd (Consumer Cyclical) Equity, Since 31 Mar 21 \| ZFCVINDIA	3%	₹1,027 Cr	700,000
City Union Bank Ltd (Financial Services) Equity, Since 30 Jun 20 \| CUB	3%	₹1,004 Cr	39,314,614
Belrise Industries Ltd (Consumer Cyclical) Equity, Since 31 Dec 25 \| BELRISE	3%	₹943 Cr	43,542,092
Krishna Institute of Medical Sciences Ltd (Healthcare) Equity, Since 30 Jun 23 \| KIMS	3%	₹935 Cr	12,323,990
Sundaram Fasteners Ltd (Consumer Cyclical) Equity, Since 28 Feb 25 \| SUNDRMFAST	2%	₹860 Cr	10,000,000

9. Invesco India Growth Opportunities Fund

(Erstwhile Invesco India Growth Fund)

The investment objective of the Scheme is to generate long-term capital growth from a diversified portfolio of predominantly equity and equity-related securities. However, there can be no assurance that the objectives of the scheme will be achieved.

Research Highlights for Invesco India Growth Opportunities Fund

Upper mid AUM (₹10,153 Cr).
Established history (18+ yrs).
Top rated.
Risk profile: Moderately High.
5Y return: 17.20% (upper mid).
3Y return: 23.23% (upper mid).
1Y return: 7.25% (lower mid).
Alpha: 2.71 (top quartile).
Sharpe: 0.07 (bottom quartile).
Information ratio: 0.87 (top quartile).
Higher exposure to Financial Services vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~99%).
Largest holding Max Healthcare Institute Ltd Ordinary Shares (~6.8%).

Below is the key information for Invesco India Growth Opportunities Fund

Invesco India Growth Opportunities Fund Growth
Launch Date	9 Aug 07
NAV (17 Jul 26)	₹109.61 ↓ -0.37 (-0.34 %)
Net Assets (Cr)	₹10,153 on 31 May 26
Category	Equity - Large & Mid Cap
AMC	Invesco Asset Management (India) Private Ltd
Rating	☆☆☆☆☆
Risk	Moderately High
Expense Ratio	1.82
Sharpe Ratio	0.07
Information Ratio	0.87
Alpha Ratio	2.71
Min Investment	5,000
Min SIP Investment	100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹9,616
30 Jun 23	₹12,058
30 Jun 24	₹18,524
30 Jun 25	₹21,406
30 Jun 26	₹22,689

Invesco India Growth Opportunities Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹470,047.
Net Profit of ₹170,047 Invest Now

Returns for Invesco India Growth Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	4.4%
3 Month	11%
6 Month	11.7%
1 Year	7.3%
3 Year	23.2%
5 Year	17.2%
10 Year
15 Year
Since launch	13.5%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	4.7%
2023	37.5%
2022	31.6%
2021	-0.4%
2020	29.7%
2019	13.3%
2018	10.7%
2017	-0.2%
2016	39.6%
2015	3.3%

Fund Manager information for Invesco India Growth Opportunities Fund

Name	Since	Tenure
Aditya Khemani	9 Nov 23	2.64 Yr.

Data below for Invesco India Growth Opportunities Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Financial Services	26.21%
Health Care	18.9%
Industrials	18.79%
Consumer Cyclical	17.87%
Real Estate	7.6%
Basic Materials	4.07%
Technology	2.71%
Communication Services	1.71%
Utility	1.37%

Asset Allocation

Asset Class	Value
Cash	0.76%
Equity	99.23%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 30 Nov 22 \| MAXHEALTH	7%	₹687 Cr	7,118,724 ↑ 170,000
Eternal Ltd (Consumer Cyclical) Equity, Since 30 Jun 23 \| ETERNAL	7%	₹684 Cr	27,307,479 ↑ 2,577,787
InterGlobe Aviation Ltd (Industrials) Equity, Since 31 Mar 24 \| INDIGO	6%	₹654 Cr	1,484,863 ↑ 95,086
ICICI Bank Ltd (Financial Services) Equity, Since 31 Dec 15 \| ICICIBANK	6%	₹646 Cr	5,141,398 ↑ 511,565
Sai Life Sciences Ltd (Healthcare) Equity, Since 31 Dec 24 \| SAILIFE	5%	₹497 Cr	4,283,799
Trent Ltd (Consumer Cyclical) Equity, Since 28 Feb 22 \| TRENT	5%	₹460 Cr	1,089,122
Prestige Estates Projects Ltd (Real Estate) Equity, Since 31 Dec 23 \| PRESTIGE	4%	₹452 Cr	3,304,450 ↑ 174,545
ABB India Ltd (Industrials) Equity, Since 30 Jun 23 \| ABB	4%	₹441 Cr	608,622 ↑ 143,577
BSE Ltd (Financial Services) Equity, Since 31 Oct 23 \| BSE	4%	₹396 Cr	955,364 ↓ -149,234
L&T Finance Ltd (Financial Services) Equity, Since 30 Apr 24 \| LTF	3%	₹325 Cr	11,339,315

10. HDFC Long Term Advantage Fund

To generate long term capital appreciation from a portfolio that is predominantly in equity and equity related instruments

Research Highlights for HDFC Long Term Advantage Fund

Bottom quartile AUM (₹1,318 Cr).
Established history (25+ yrs).
Rating: 3★ (upper mid).
Risk profile: Moderately High.
5Y return: 17.39% (top quartile).
3Y return: 20.64% (upper mid).
1Y return: 35.51% (top quartile).
Alpha: 1.75 (upper mid).
Sharpe: 2.27 (top quartile).
Information ratio: -0.15 (lower mid).

Below is the key information for HDFC Long Term Advantage Fund

HDFC Long Term Advantage Fund Growth
Launch Date	2 Jan 01
NAV (14 Jan 22)	₹595.168 ↑ 0.28 (0.05 %)
Net Assets (Cr)	₹1,318 on 30 Nov 21
Category	Equity - ELSS
AMC	HDFC Asset Management Company Limited
Rating	☆☆☆
Risk	Moderately High
Expense Ratio	2.25
Sharpe Ratio	2.27
Information Ratio	-0.15
Alpha Ratio	1.75
Min Investment	500
Min SIP Investment	500
Exit Load	NIL

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000

HDFC Long Term Advantage Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹470,047.
Net Profit of ₹170,047 Invest Now

Purchase not allowed

Returns for HDFC Long Term Advantage Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	4.4%
3 Month	1.2%
6 Month	15.4%
1 Year	35.5%
3 Year	20.6%
5 Year	17.4%
10 Year
15 Year
Since launch	21.4%

Historical performance (Yearly) on absolute basis

Year	Returns
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Fund Manager information for HDFC Long Term Advantage Fund

Name	Since	Tenure

Data below for HDFC Long Term Advantage Fund as on 30 Nov 21

Equity Sector Allocation

Sector	Value

Asset Allocation

Asset Class	Value

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity

11. DSP Small Cap Fund

(Erstwhile DSP BlackRock Micro Cap Fund)

The primary investment objective is to seek to generate long term capital appreciation from a portfolio that is substantially constituted of equity and equity related securities of small cap companies. From time to time, the fund manager will also seek participation in other equity and equity related securities to achieve optimal portfolio construction. There is no assurance that the investment objective of the Scheme will be realized

Research Highlights for DSP Small Cap Fund

Upper mid AUM (₹18,358 Cr).
Established history (19+ yrs).
Rating: 4★ (upper mid).
Risk profile: Moderately High.
5Y return: 17.11% (upper mid).
3Y return: 18.02% (lower mid).
1Y return: 7.97% (lower mid).
Alpha: 0.00 (upper mid).
Sharpe: 0.13 (lower mid).
Information ratio: 0.00 (upper mid).
Higher exposure to Consumer Cyclical vs peer median.
Higher exposure to Cash Equivalent (bond sector) vs peer median.
Equity-heavy allocation (~90%).
Largest holding Lumax Auto Technologies Ltd (~5.0%).

Below is the key information for DSP Small Cap Fund

DSP Small Cap Fund Growth
Launch Date	14 Jun 07
NAV (17 Jul 26)	₹221.566 ↓ -1.46 (-0.65 %)
Net Assets (Cr)	₹18,358 on 31 May 26
Category	Equity - Small Cap
AMC	DSP BlackRock Invmt Managers Pvt. Ltd.
Rating	☆☆☆☆
Risk	Moderately High
Expense Ratio	1.72
Sharpe Ratio	0.13
Information Ratio	0
Alpha Ratio	0
Min Investment	1,000
Min SIP Investment	500
Exit Load	0-12 Months (1%),12 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹10,594
30 Jun 23	₹13,804
30 Jun 24	₹19,548
30 Jun 25	₹21,421
30 Jun 26	₹23,103

DSP Small Cap Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹470,047.
Net Profit of ₹170,047 Invest Now

Returns for DSP Small Cap Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 26

Duration	Returns
1 Month	4.3%
3 Month	10.2%
6 Month	15.9%
1 Year	8%
3 Year	18%
5 Year	17.1%
10 Year
15 Year
Since launch	17.6%

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-2.8%
2023	25.6%
2022	41.2%
2021	0.5%
2020	58.9%
2019	33.1%
2018	0.7%
2017	-25.5%
2016	42.8%
2015	12.7%

Fund Manager information for DSP Small Cap Fund

Name	Since	Tenure
Vinit Sambre	21 Jun 10	16.04 Yr.

Data below for DSP Small Cap Fund as on 31 May 26

Equity Sector Allocation

Sector	Value
Consumer Cyclical	31.79%
Industrials	16.23%
Basic Materials	15.28%
Health Care	9.25%
Financial Services	8.24%
Consumer Defensive	6.15%
Technology	2.11%
Communication Services	0.44%

Asset Allocation

Asset Class	Value
Cash	10.5%
Equity	89.5%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Lumax Auto Technologies Ltd (Consumer Cyclical) Equity, Since 30 Jun 18 \| LUMAXTECH	5%	₹921 Cr	5,337,441 ↓ -600,000
Kirloskar Oil Engines Ltd (Industrials) Equity, Since 31 Mar 23 \| 533293	4%	₹725 Cr	3,762,866
Thangamayil Jewellery Ltd (Consumer Cyclical) Equity, Since 30 Nov 21 \| THANGAMAYL	3%	₹628 Cr	1,493,620 ↓ -91,335
Sansera Engineering Ltd (Consumer Cyclical) Equity, Since 30 Jun 24 \| SANSERA	3%	₹506 Cr	1,770,029
Welspun Corp Ltd (Basic Materials) Equity, Since 31 Mar 21 \| WELCORP	3%	₹470 Cr	3,411,788 ↓ -343,883
Jubilant Ingrevia Ltd Ordinary Shares (Basic Materials) Equity, Since 31 Dec 22 \| JUBLINGREA	2%	₹450 Cr	6,970,677 ↓ -29,323
Dodla Dairy Ltd (Consumer Defensive) Equity, Since 30 Jun 21 \| DODLA	2%	₹405 Cr	3,750,000
LT Foods Ltd (Consumer Defensive) Equity, Since 31 Dec 17 \| LTFOODS	2%	₹392 Cr	10,000,000
SPR Auto Technologies Ltd (Consumer Cyclical) Equity, Since 31 Aug 24 \| SHRIPISTON	2%	₹367 Cr	1,081,165
eClerx Services Ltd (Technology) Equity, Since 28 Feb 18 \| ECLERX	2%	₹334 Cr	2,211,836

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.